Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amazon

Alibaba

iCAD

Nikola

Starbucks

XPeng

New CEOs can breathe new life into a company by launching new initiatives, hiring more effective managers, and/or entering new markets. One great example is General Electric.

CEO Shuffle: 7 Stocks That Could Gain Momentum From New Leadership

NanoString Technologies

Natera

10X Genomics

The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive measures to maintain the well-being of larger populations.

Red-Hot Quality Opportunities in Genomics

SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Illumina Ventures, a leading genomics and precision health venture firm, today announced plans to launch Illumina Ventures Labs.

Illumina Ventures to Launch Illumina® Ventures Labs

Agilent Technologies

Waters

Investors seeking growth often have no choice other than paying up for a stock with strong potential. However, there are some stocks that appear to be trading at low valuations relative to their growth potential.

Medicals Stocks Waters, Agilent, Illumina Show Growth Potential

Illumina's CEO resigned after its recent battles with regulators and shareholders. Its core segments aren't growing like they used to.

Illumina's CEO Was Just Ousted: Should Investors Buy In Now or Steer Clear?

23andMe

Myriad Genetics

Genes are the foundation of human life. They are the code that gives every instruction to our bodies about how to move, digest and think.

3 Gene Testing Stocks to Buy Before They Take Off

And we interview Anjay Nagpal, host of the podcast "Brokers, Bagmen, and Moles."

Illumina CEO Steps Down; Grail Soap Opera Continues

The groups argued in the briefs that the FTC overstepped its authority in trying to unwind Illumina's $7.1 billion acquisition of Grail.

Illumina acquisition of Grail wins support from GOP lawmakers, state AGs as FTC tries to block

Illumina, Inc. (NASDAQ:ILMN ) Special Call (2023 ESG Investor Event) Transcript June 12, 2023 12:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Joydeep Goswami - Chief Financial Officer and Chief Strategy and Corporate Development Officer Phil Febbo - Chief Medical Officer John Frank - Chief Public Affairs Officer Sharon Vidal - Head of Corporate Social Responsibility and ESG Lisa Toppin - Global Head of Diversity, Equity and Inclusion Conference Call Participants Operator Good day attendees and welcome to the Illumina Incorporated ESG Investor Event. At this time, all participants are in listen-only mode.

Illumina, Inc. (ILMN) Special Call (2023 ESG Investor Event) Transcript

Francis deSouza resigned from gene-sequencing maker after regulators challenged $7.1 billion deal, triggering proxy battle with Carl Icahn.

After Illumina CEO's Fall, Other Executives May Take Hard Look Before Deal Making

Carl Icahn may be about to work his magic on another company. This week, reports surfaced that Illumina (NASDAQ: ILMN ) is gearing up for a change in leadership.

Is CEO Resignation a Sign That Carl Icahn Can Save Illumina (ILMN) Stock?

Illumina Inc (NASDAQ:ILMN), which has faced a bruising battle with activist investor Carl Icahn, said CEO Francis deSouza resigned as CEO with immediate effect on Sunday. The gene sequencing company named senior vice president and general counsel Charles Dadswell interim CEO while it searches for a new CEO, adding that deSouza will stay on in an advisory capacity until July 31, 2023.

Illumina CEO resigns after proxy battle with Icahn

Illumina Inc. ILMN, -1.08% stock gained 4.7% premarket on Monday after the company announced Sunday that its board had accepted the resignation of Francis deSouza as CEO, effective immediately. The company named Charles Dadswell, senior vice president and general counsel, as interim CEO, and deSouza will stay on in an advisory capacity until the end of July, the company said in a release.

Illumina shares rise after CEO resignation

NEW YORK — Gene sequencing test maker Illumina Inc. said Sunday that its board has accepted the resignation of its CEO and director, Francis deSouza, effective immediately.

Illumina CEO resigns amid pressure from activist investor Carl Icahn

Illumina Inc (NASDAQ: ILMN), on Sunday, said its board has accepted resignation from CEO Francis deSouza who's been leading the gene sequencing company since 2016. Charles Dadswell named interim CEO The biotech giant has already started looking or a new chief executive.

Francis deSouza just resigned as the CEO of Illumina Inc

Illumina announced its board of directors has accepted the resignation of CEO Francis deSouza Sunday.

Illumina announces CEO transition plan as Francis deSouza resigns

Head of gene-sequencing test maker steps aside after regulators challenged deal for a cancer test-developer.

Illumina CEO Francis deSouza Resigns

SAN DIEGO , June 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina's Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior Vice President and General Counsel, has been named interim CEO while the Board of Directors conducts a search for a new CEO.

Illumina announces CEO transition plan

Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.

Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger

SAN DIEGO , June 5, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report , highlighting the company's commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022. "Genomics has the ability to improve global health care, sustainability, and equity through better diagnosis and treatment; better representation in genomic data; greater access to personalized medicine; and a deeper understanding of the world," said Francis deSouza, CEO of Illumina.

Illumina releases 2022 Corporate Social Responsibility Report

Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Illumina's (ILMN) New AI Tool to Predict Genomics Disease

Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina's Board Scott B. Ullem, CFO of Edwards Lifesciences, also named to Board SAN DIEGO , June 2, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes consistent with the goal of enhancing long-term shareholder value.

Illumina's Board of Directors elects two experienced Independent Directors to Board

Published findings demonstrate PrimateAI-3D's ability to improve genetic risk prediction and drug target discovery using primate DNA and advanced artificial intelligence SAN DIEGO , June 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients. The results are published in two papers in the June 2 issue of Science (issue 6648), detailing the training of the algorithm and its application to half a million genomes in the UK Biobank cohort.

Illumina unveils AI software to predict disease-causing genetic mutations in patients

Illumina is undervalued by 23% according to a discounted cash flow analysis, with a fair value of $253.94. The company aims to expand into the $120bn TAM industries of oncology testing, genetic disease testing, reproductive health, and research and applied healthcare products. Risks include dependence on sustained innovation and extraneous market demand and potential Grail divestment.

The Market Continues To Underprice Illumina's Stock And Its Genomics Leadership

SAN DIEGO , May 31, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will host its third annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:00 am Pacific Time (12:00 pm Eastern Time), Monday, June 12, 2023. Francis deSouza, Chief Executive Officer, Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, Aimee Hoyt, Chief People Officer, Phil Febbo, M.D.

News for Illumina Stock (ILMN)